MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.20
-0.10
-0.97%
Closed 16:48 05/05 EDT
OPEN
10.24
PREV CLOSE
10.30
HIGH
10.55
LOW
10.06
VOLUME
875.58K
TURNOVER
--
52 WEEK HIGH
13.44
52 WEEK LOW
0.7200
MARKET CAP
933.49M
P/E (TTM)
-15.1134
1D
5D
1M
3M
1Y
5Y
Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2021 financial results on Wednesday, May 12, 2021, after ...
PR Newswire · 1d ago
Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 1d ago
Alliance Wealth Management Group Buys Invesco Fundamental High Yield Corporate Bond ETF, Curis ...
GuruFocus News · 2d ago
Curis Stock Shows Every Sign Of Being Significantly Overvalued
GuruFocus News · 2d ago
DJ Curis Gets FDA Orphan Designation for CA-4948 in AML, MDS >CRIS
Dow Jones · 04/19 12:21
BRIEF-Curis Receives FDA Orphan Drug Designation for CA-4948
reuters.com · 04/19 12:06
Curis Receives FDA Orphan Drug Designation For CA-4948 For The Treatment Of AML and MDS
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted
Benzinga · 04/19 12:01
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
LEXINGTON, Mass., April 19, 2021 /PRNewswire via COMTEX/ -- LEXINGTON, Mass., April 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology...
PR Newswire - PRF · 04/19 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRIS. Analyze the recent business situations of Curis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRIS stock price target is 17.20 with a high estimate of 19.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 115
Institutional Holdings: 67.32M
% Owned: 73.55%
Shares Outstanding: 91.52M
TypeInstitutionsShares
Increased
27
7.77M
New
50
42.00M
Decreased
13
4.38M
Sold Out
8
2.51M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Independent Director
Martyn Greenacre
President/Chief Executive Officer/Director
James Dentzer
Chief Financial Officer
William Steinkrauss
Other
Robert Martell
Independent Director
Kenneth Kaitin
Independent Director
Lori Kunkel
Independent Director
Marc Rubin
No Data
  • All
  • Financials
  • Insiders
More
About CRIS
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Webull offers kinds of Curis, Inc. stock information, including NASDAQ:CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.